ResearcherNagoya UniversityActive in the last 2 years
Hideki Kasuya
Known by name at one institution; no external author ID yet. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 3, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 16
2011: 1 paper · 2012: none · 2013: none · 2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 1 paper
Papers 5
- Enhancing mesothelin CAR T cell therapy for pancreatic cancer with an oncolytic herpes virus boosting CAR target antigen expression. Last author DOI 10.1007/s00262-025-04039-7↗
- C-REV Retains High Infectivity Regardless of the Expression Levels of cGAS and STING in Cultured Pancreatic Cancer Cells. Last author DOI 10.3390/cells10061502↗
- A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer. First author DOI 10.1186/s12885-018-4453-z↗
- Combination treatment of human pancreatic cancer xenograft models with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib and oncolytic h… First author DOI 10.1245/s10434-013-3329-3↗
- A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancr… First author DOI 10.1038/cgt.2010.65↗
Closest collaborators
The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Ibrahim Ragab Eissa · 2 shared papers, 2021–2025 · strength 0.36
- Paper Enhancing mesothelin CAR T cell therapy for pancreatic cancer with an oncolytic herpes virus boosting CAR target antige… DOI 10.1007/s00262-025-04039-7↗
- Paper C-REV Retains High Infectivity Regardless of the Expression Levels of cGAS and STING in Cultured Pancreatic Cancer Cell… DOI 10.3390/cells10061502↗
- Mona Alhussein Aboalela · 1 shared paper, 2025 · strength 0.25
- Yasuhiro Kodera · 4 shared papers, 2011–2021 · strength 0.24
- Paper C-REV Retains High Infectivity Regardless of the Expression Levels of cGAS and STING in Cultured Pancreatic Cancer Cell… DOI 10.3390/cells10061502↗
- Paper A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally adv… DOI 10.1186/s12885-018-4453-z↗
- Paper Combination treatment of human pancreatic cancer xenograft models with the epidermal growth factor receptor tyrosine ki… DOI 10.1245/s10434-013-3329-3↗
- Daishi Morimoto · 1 shared paper, 2021 · strength 0.12
- Takuya Ishikawa · 1 shared paper, 2018 · strength 0.07
- Hidemi Goto · 1 shared paper, 2018 · strength 0.07
- Hiroki Kawashima · 1 shared paper, 2018 · strength 0.07
- Eizaburo Ohno · 1 shared paper, 2018 · strength 0.07
- Yoshiki Hirooka · 1 shared paper, 2018 · strength 0.07
- Suguru Yamada · 2 shared papers, 2011–2014 · strength 0.05
- Paper Combination treatment of human pancreatic cancer xenograft models with the epidermal growth factor receptor tyrosine ki… DOI 10.1245/s10434-013-3329-3↗
- Paper A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non… DOI 10.1038/cgt.2010.65↗
- Hiroyuki Sugimoto · 2 shared papers, 2011–2014 · strength 0.05
- Paper Combination treatment of human pancreatic cancer xenograft models with the epidermal growth factor receptor tyrosine ki… DOI 10.1245/s10434-013-3329-3↗
- Paper A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non… DOI 10.1038/cgt.2010.65↗
- Tsutomu Fujii · 2 shared papers, 2011–2014 · strength 0.05
- Paper Combination treatment of human pancreatic cancer xenograft models with the epidermal growth factor receptor tyrosine ki… DOI 10.1245/s10434-013-3329-3↗
- Paper A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non… DOI 10.1038/cgt.2010.65↗
- Mitsuro Kanda · 1 shared paper, 2014 · strength 0.03
- Kazuo Yamamura · 1 shared paper, 2014 · strength 0.03
- Yukihiro Nishiyama · 1 shared paper, 2011 · strength 0.02
- Akimasa Nakao · 1 shared paper, 2011 · strength 0.02
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.